Hikma Pharmaceuticals Plc Director/PDMR Shareholding (3549N)
May 15 2015 - 8:25AM
UK Regulatory
TIDMHIK
RNS Number : 3549N
Hikma Pharmaceuticals Plc
15 May 2015
Hikma Pharmaceuticals PLC - LTIP Awards
LONDON, 15 May 2015: Hikma Pharmaceuticals PLC (LSE: HIK)
(NasdaqDubai: HIK) announces that the Remuneration Committee has
made the following conditional awards under the Hikma
Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to
certain Persons Discharging Managerial Responsibility ("PDMR") of
the Company.
Following shareholder approval at the AGM on 14 May 2015, the
awards under the EIP were made automatically on 15 May 2015 at a
price of 1,981 pence per Ordinary Share (being the average price
for the 30 day period prior to 31 December 2014, in accordance with
the EIP rules) as follows:
PDMR Element B Element C
Shares Shares
Said Darwazah 41,000 27,000
Mazen Darwazah 30,000 20,000
The Element B share awards will be released to the participants
in two years' time subject to their continued employment and the
non-occurrence of forfeiture events during the vesting period as
judged by the Remuneration Committee at each anniversary of the
grant.
The Element C share awards will be released to the participants
in three years' time subject to their continued employment.
These participants are not allowed to sell 50% of the vested
shares under elements B and C until five years.
Further details on the EIP, forfeiture criteria and holding
period can be found in Hikma's report and accounts for the year
ended 31 December 2014 on pages 98, 103 and 104.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs +44 20 7399 2760
Company Secretary
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2014, Hikma achieved
revenues of $1,489 million and profit attributable to shareholders
of $278 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSBDGDUDDBBGUU
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024